A PET‐Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers

Advanced Science, Год журнала: 2024, Номер 11(28)

Опубликована: Май 17, 2024

Abstract Metabolic alterations in cancers can be exploited for diagnostic, prognostic, and therapeutic purposes. This is exemplified by 18F‐fluorodeoxyglucose (FDG)‐positron emission tomography (FDG‐PET), an imaging tool that relies on enhanced glucose uptake tumors diagnosis staging. By performing transcriptomic analysis of breast cancer (BC) samples from patients stratified FDG‐PET, a 54‐gene signature (PETsign) identified recapitulates FDG uptake. PETsign independently prognostic clinical outcome luminal BCs, the most common heterogeneous BC molecular subtype, which requires improved stratification criteria to guide decision‐making. The power stable across independent cohorts disease stages including earliest stage, arguing ab initio metabolic signature. Transcriptomic metabolomic cells reveals predicts glycolytic dependence reduced reliance fatty acid oxidation. Moreover, coamplification genes occurs frequently their causal role pathogenesis. CXCL8 EGFR signaling pathways feature strongly PETsign, activation causes shift toward phenotype. Thus, serves as surrogate FDG‐PET could inform management strategies patients.

Язык: Английский

Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype

Current Issues in Molecular Biology, Год журнала: 2024, Номер 47(1), С. 4 - 4

Опубликована: Дек. 25, 2024

Amino acid metabolism in breast cancer cells is unique for each molecular biological subtype of cancer. In this review, the features cell are considered terms changes amino composition due to activity transmembrane transporters. addition main signaling pathway PI3K/Akt/mTOR, oncogene c-Myc, HIF, p53, GATA2, NF-kB and MAT2A have a direct effect on cells, their growth proliferation, as well maintenance homeostatic equilibrium. A distinctive feature luminal subtypes from TNBC ability perform gluconeogenesis. Breast cancers with positive expression HER2 receptor, contrast subtype, active synthesis consumption fatty acids. It interesting note that transporters exhibit depending pH level inside cell. most aggressive forms or gradual progression disease, will also change, which directly affect Using lines presented we can trace characteristic inherent develop optimal therapeutic targets.

Язык: Английский